Direct Offering

Lexaria Bioscience Secures $4 Million in Capital Through Registered Direct Offering

Lexaria Bioscience Corp. has raised $4 million through a registered direct offering, providing crucial working capital to advance its DehydraTECH drug delivery platform technology.